Open AccessRapid Identification of Buprenorphine in Patient Saliva
Author(s) -
Stuart Farquharson,
Kathryn Dana,
Chetan Shende,
Zachary Gladding,
Jenelle Newcomb,
Jessica Dascher,
Ismene L. Petrakis,
Albert J. Arias
Publication year - 2017
Publication title -
journal of analytical and bioanalytical techniques
Language(s) - English
Resource type - Journals
ISSN - 2155-9872
DOI - 10.4172/2155-9872.1000368
Subject(s) - saliva , buprenorphine , medicine , heroin , chromatography , drug detection , methadone , opioid , drug , pharmacology , chemistry , receptor
Buprenorphine is becoming the medication of choice to help patients withdraw from opioid addiction. However, treatment is compromised by the inability of physicians to assess patient usage during scheduled examinations. Here we describe the development of a point-of-care (POC) analyzer that can rapidly measure both illicit and treatment drugs in patient saliva, ideally in the physician’s office, and with a degree of accuracy similar to chromatography. The analyzer employs a relatively simple supported liquid extraction to isolate the drugs from the saliva and surface-enhanced Raman spectroscopy (SERS) to detect the drugs. The SERS-based POC analyzer was used to identify buprenorphine and opioids in saliva samples by matching library spectra to samples collected from 7 veterans. The total analysis time, including sample preparation, was ~25 minutes. Buprenorphine concentration was estimated between 0 and 3 μg/mL. While no other prescription opioids were detected in any samples, heroin was identified in one sample; Δ-9 tetrahydrocannabinol (THC) was detected in 3 samples; and acetaminophen, caffeine, and nicotine were detected in several samples, none of which interfered with the measurements. The analysis was in very good agreement with urinalysis, correctly identifying the presence or absence of buprenorphine and THC in 13 of 14 measurements.